Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

被引：24
作者：
Nastoupil, Loretta J. [1 ,3 ]
Bartlett, Nancy L. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[3] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 04期
关键词：
RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PREVIOUSLY UNTREATED PATIENTS; SOUTHWEST-ONCOLOGY-GROUP; NON-HODGKIN-LYMPHOMA; DOUBLE-HIT LYMPHOMA; SINGLE-ARM; OPEN-LABEL; ELDERLY-PATIENTS; PHASE-III; R-CHOP;
D O I：
10.1200/JCO.22.01848
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
引用
收藏
页码：903 / +
页数：12
相关论文
共 50 条
  • [31] Guidelines for the management of diffuse large B-cell lymphoma
    Chaganti, Sridhar
    Illidge, Tim
    Barrington, Sally
    Mckay, Pam
    Linton, Kim
    Cwynarski, Kate
    McMillan, Andrew
    Davies, Andy
    Stern, Simon
    Peggs, Karl
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 43 - 56
  • [32] Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature
    Yamasaki, Satoshi
    HEMATOLOGY REPORTS, 2024, 16 (02) : 317 - 330
  • [33] Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
    Vodicka, Prokop
    Klener, Pavel
    Trneny, Marek
    ONCOTARGETS AND THERAPY, 2022, 15 : 1481 - 1501
  • [34] Genetic Profiling in Diffuse Large B-Cell Lymphoma: The Promise and the Challenge
    Cutmore, Natasha H.
    Krupka, Joanna A.
    Hodson, Daniel J.
    MODERN PATHOLOGY, 2023, 36 (01)
  • [35] Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
    Tilly, H.
    Gomes da Silva, M.
    Vitolo, U.
    Jack, A.
    Meignan, M.
    Lopez-Guillermo, A.
    Walewski, J.
    Andre, M.
    Johnson, P. W.
    Pfreundschuh, M.
    Ladetto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : V116 - V125
  • [36] Diagnosis and treatment of diffuse large B-cell lymphoma
    Mey, Ulrich
    Hitz, Felicitas
    Lohri, Andreas
    Pederiva, Stefanie
    Taverna, Christian
    Tzankov, Alexander
    Meier, Oliver
    Yeow, Karen
    Renner, Christoph
    SWISS MEDICAL WEEKLY, 2012, 142
  • [37] Pidilizumab in the treatment of diffuse large B-cell lymphoma
    Bryan, Locke J.
    Gordon, Leo I.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (09) : 1361 - 1368
  • [38] Diffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies
    Lue, Jennifer K.
    Nowakowski, Grzegorz S.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [39] Diffuse large B-cell lymphoma with MYC gene rearrangements Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature
    de Jonge, A. V.
    Roosma, T. J. A.
    Houtenbos, I.
    Vasmel, W. L. E.
    van de Hem, K.
    de Boer, J. P.
    van Maanen, T.
    Lindauer-van der Werf, G.
    Beeker, A.
    Timmers, G. J.
    Schaar, C. G.
    Soesan, M.
    Poddighe, P. J.
    de Jong, D.
    Chamuleau, M. E. D.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : 140 - 146
  • [40] Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
    Frontzek, Fabian
    Karsten, Imke
    Schmitz, Norbert
    Lenz, Georg
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
12345